Antibiotic Exposure Concurrently with Anti-PD1 Blockade Therapy Reduces Overall Survival in Patients with Child-Pugh Class A Advanced Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide with a poor prognosis. Treatment with immune checkpoint inhibitors (ICIs) has improved overall survival in patients with HCC. However, not all patients benefit from the treatment. In this study, 59 patients with HCC...
Gespeichert in:
| Veröffentlicht in: | Cancers 2023-12, Vol.16 (1), p.133 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 133 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Alshammari, Kanan Alotaibi, Faizah M Alsugheir, Futoon Aldawoud, Mohammad Alolayan, Ashwaq Algarni, Mohammed Ahmad Sabatin, Fouad Mohammad, Mohammad F Alosaimi, Abdulaziz Sanai, Faisal M Odah, Hassan Alshehri, Ahmed Saleh Aldibasi, Omar S Alrehaily, Samah Al Saleh, Abdullah S |
| description | Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide with a poor prognosis. Treatment with immune checkpoint inhibitors (ICIs) has improved overall survival in patients with HCC. However, not all patients benefit from the treatment. In this study, 59 patients with HCC were enrolled from two medical centers in Saudi Arabia, with 34% using antibiotics concurrently with their Nivolumab (anti-PD1 blockade). The impact of antibiotic use on the clinical outcomes of patients with HCC undergoing treatment with anti-PD1 blockade was examined. The patients' overall survival (OS) was 5 months (95% CI: 3.2, 6.7) compared to 10 months (95% CI: 0, 22.2) (
= 0.08). Notably, patients with Child-Pugh A cirrhosis receiving anti-PD1 blockade treatment without concurrent antibiotic use showed a significantly longer median OS reaching 22 months (95% CI: 6.5, 37.4) compared to those who were given antibiotics with a median OS of 6 months (95% CI: 2.7, 9.2) (
= 0.02). This difference in overall survival was particularly found in Child-Pugh class A patients receiving anti-PD1 blockade. These findings suggest that antibiotic use may negatively affect survival outcomes in HCC patients undergoing anti-PD1 blockade, potentially due to antibiotic-induced alterations to the gut microbiome impacting the anti-PD1 blockade response. This study suggests the need for careful consideration when prescribing antibiotics to patients with HCC receiving anti-PD1 blockade. |
| doi_str_mv | 10.3390/cancers16010133 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10777962</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A779132443</galeid><sourcerecordid>A779132443</sourcerecordid><originalsourceid>FETCH-LOGICAL-c489t-bf35d66a6159bacac6fe5e8a043858bca8e340f40f59c1ec212a4405b7275703</originalsourceid><addsrcrecordid>eNptkk1vEzEQhlcIRKvSMzdkiQuXbf2x3o8TCqGlSJUaQe7WrHc2cXHsYO8G8mf4rfUqpbQVtiWP7Wde-7Umy94yeiZEQ881OI0hspIyyoR4kR1zWvG8LJvi5aP4KDuN8ZamJgSryup1diRqTpks6XH2Z-YG0xo_GE0ufm99HAOSuXd6DAHdYPfklxnWZKLyxWdGPlmvf0CHZLnGANs9-YbdqDGSm11aW0u-j2FndmCJcWQBg0ki8aAxXxvb5YtxlUILMZIZmXW7yUNHrnALg9do7WghkDkEbZzfwJvsVQ824un9fJItLy-W86v8-ubL1_nsOtdF3Qx52wvZlSWUTDYtaNBljxJroIWoZd1qqFEUtE9DNpqh5oxDUVDZVrySFRUn2ceD7HZsN9jp9OhkRm2D2UDYKw9GPT1xZq1WfqcYraqqKXlS-HCvEPzPEeOgNiZOfsChH6PiDROFpI1kCX3_DL31Y3DJ3kRxWTQV4_-oFVhUxvU-XawnUTVLVzLBi0Ik6uw_VOodboz2DnuT9p8knB8SdPAxBuwfTDKqpqpSz6oqZbx7_DcP_N8aEnfzs8pX</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2912549712</pqid></control><display><type>article</type><title>Antibiotic Exposure Concurrently with Anti-PD1 Blockade Therapy Reduces Overall Survival in Patients with Child-Pugh Class A Advanced Hepatocellular Carcinoma</title><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Alshammari, Kanan ; Alotaibi, Faizah M ; Alsugheir, Futoon ; Aldawoud, Mohammad ; Alolayan, Ashwaq ; Algarni, Mohammed Ahmad ; Sabatin, Fouad ; Mohammad, Mohammad F ; Alosaimi, Abdulaziz ; Sanai, Faisal M ; Odah, Hassan ; Alshehri, Ahmed Saleh ; Aldibasi, Omar S ; Alrehaily, Samah ; Al Saleh, Abdullah S</creator><creatorcontrib>Alshammari, Kanan ; Alotaibi, Faizah M ; Alsugheir, Futoon ; Aldawoud, Mohammad ; Alolayan, Ashwaq ; Algarni, Mohammed Ahmad ; Sabatin, Fouad ; Mohammad, Mohammad F ; Alosaimi, Abdulaziz ; Sanai, Faisal M ; Odah, Hassan ; Alshehri, Ahmed Saleh ; Aldibasi, Omar S ; Alrehaily, Samah ; Al Saleh, Abdullah S</creatorcontrib><description>Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide with a poor prognosis. Treatment with immune checkpoint inhibitors (ICIs) has improved overall survival in patients with HCC. However, not all patients benefit from the treatment. In this study, 59 patients with HCC were enrolled from two medical centers in Saudi Arabia, with 34% using antibiotics concurrently with their Nivolumab (anti-PD1 blockade). The impact of antibiotic use on the clinical outcomes of patients with HCC undergoing treatment with anti-PD1 blockade was examined. The patients' overall survival (OS) was 5 months (95% CI: 3.2, 6.7) compared to 10 months (95% CI: 0, 22.2) (
= 0.08). Notably, patients with Child-Pugh A cirrhosis receiving anti-PD1 blockade treatment without concurrent antibiotic use showed a significantly longer median OS reaching 22 months (95% CI: 6.5, 37.4) compared to those who were given antibiotics with a median OS of 6 months (95% CI: 2.7, 9.2) (
= 0.02). This difference in overall survival was particularly found in Child-Pugh class A patients receiving anti-PD1 blockade. These findings suggest that antibiotic use may negatively affect survival outcomes in HCC patients undergoing anti-PD1 blockade, potentially due to antibiotic-induced alterations to the gut microbiome impacting the anti-PD1 blockade response. This study suggests the need for careful consideration when prescribing antibiotics to patients with HCC receiving anti-PD1 blockade.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16010133</identifier><identifier>PMID: 38201560</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Antibiotics ; Bacterial infections ; Care and treatment ; Cirrhosis ; Hepatitis ; Hepatocellular carcinoma ; Hepatoma ; Immune checkpoint inhibitors ; Immune system ; Immunotherapy ; Intestinal microflora ; Ipilimumab ; Kidney diseases ; Kinases ; Ligands ; Liver cancer ; Liver cirrhosis ; Medical research ; Medicine, Experimental ; Microbiomes ; Microbiota ; Microorganisms ; Patient outcomes ; Patients ; PD-1 protein ; Survival ; Urinary tract infections</subject><ispartof>Cancers, 2023-12, Vol.16 (1), p.133</ispartof><rights>COPYRIGHT 2023 MDPI AG</rights><rights>2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 by the authors. 2023</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c489t-bf35d66a6159bacac6fe5e8a043858bca8e340f40f59c1ec212a4405b7275703</citedby><cites>FETCH-LOGICAL-c489t-bf35d66a6159bacac6fe5e8a043858bca8e340f40f59c1ec212a4405b7275703</cites><orcidid>0000-0001-7795-3609 ; 0000-0002-4120-577X ; 0000-0002-6712-7888 ; 0000-0002-1626-1059</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10777962/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10777962/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38201560$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alshammari, Kanan</creatorcontrib><creatorcontrib>Alotaibi, Faizah M</creatorcontrib><creatorcontrib>Alsugheir, Futoon</creatorcontrib><creatorcontrib>Aldawoud, Mohammad</creatorcontrib><creatorcontrib>Alolayan, Ashwaq</creatorcontrib><creatorcontrib>Algarni, Mohammed Ahmad</creatorcontrib><creatorcontrib>Sabatin, Fouad</creatorcontrib><creatorcontrib>Mohammad, Mohammad F</creatorcontrib><creatorcontrib>Alosaimi, Abdulaziz</creatorcontrib><creatorcontrib>Sanai, Faisal M</creatorcontrib><creatorcontrib>Odah, Hassan</creatorcontrib><creatorcontrib>Alshehri, Ahmed Saleh</creatorcontrib><creatorcontrib>Aldibasi, Omar S</creatorcontrib><creatorcontrib>Alrehaily, Samah</creatorcontrib><creatorcontrib>Al Saleh, Abdullah S</creatorcontrib><title>Antibiotic Exposure Concurrently with Anti-PD1 Blockade Therapy Reduces Overall Survival in Patients with Child-Pugh Class A Advanced Hepatocellular Carcinoma</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide with a poor prognosis. Treatment with immune checkpoint inhibitors (ICIs) has improved overall survival in patients with HCC. However, not all patients benefit from the treatment. In this study, 59 patients with HCC were enrolled from two medical centers in Saudi Arabia, with 34% using antibiotics concurrently with their Nivolumab (anti-PD1 blockade). The impact of antibiotic use on the clinical outcomes of patients with HCC undergoing treatment with anti-PD1 blockade was examined. The patients' overall survival (OS) was 5 months (95% CI: 3.2, 6.7) compared to 10 months (95% CI: 0, 22.2) (
= 0.08). Notably, patients with Child-Pugh A cirrhosis receiving anti-PD1 blockade treatment without concurrent antibiotic use showed a significantly longer median OS reaching 22 months (95% CI: 6.5, 37.4) compared to those who were given antibiotics with a median OS of 6 months (95% CI: 2.7, 9.2) (
= 0.02). This difference in overall survival was particularly found in Child-Pugh class A patients receiving anti-PD1 blockade. These findings suggest that antibiotic use may negatively affect survival outcomes in HCC patients undergoing anti-PD1 blockade, potentially due to antibiotic-induced alterations to the gut microbiome impacting the anti-PD1 blockade response. This study suggests the need for careful consideration when prescribing antibiotics to patients with HCC receiving anti-PD1 blockade.</description><subject>Antibiotics</subject><subject>Bacterial infections</subject><subject>Care and treatment</subject><subject>Cirrhosis</subject><subject>Hepatitis</subject><subject>Hepatocellular carcinoma</subject><subject>Hepatoma</subject><subject>Immune checkpoint inhibitors</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Intestinal microflora</subject><subject>Ipilimumab</subject><subject>Kidney diseases</subject><subject>Kinases</subject><subject>Ligands</subject><subject>Liver cancer</subject><subject>Liver cirrhosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Microbiomes</subject><subject>Microbiota</subject><subject>Microorganisms</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>PD-1 protein</subject><subject>Survival</subject><subject>Urinary tract infections</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1vEzEQhlcIRKvSMzdkiQuXbf2x3o8TCqGlSJUaQe7WrHc2cXHsYO8G8mf4rfUqpbQVtiWP7Wde-7Umy94yeiZEQ881OI0hspIyyoR4kR1zWvG8LJvi5aP4KDuN8ZamJgSryup1diRqTpks6XH2Z-YG0xo_GE0ufm99HAOSuXd6DAHdYPfklxnWZKLyxWdGPlmvf0CHZLnGANs9-YbdqDGSm11aW0u-j2FndmCJcWQBg0ki8aAxXxvb5YtxlUILMZIZmXW7yUNHrnALg9do7WghkDkEbZzfwJvsVQ824un9fJItLy-W86v8-ubL1_nsOtdF3Qx52wvZlSWUTDYtaNBljxJroIWoZd1qqFEUtE9DNpqh5oxDUVDZVrySFRUn2ceD7HZsN9jp9OhkRm2D2UDYKw9GPT1xZq1WfqcYraqqKXlS-HCvEPzPEeOgNiZOfsChH6PiDROFpI1kCX3_DL31Y3DJ3kRxWTQV4_-oFVhUxvU-XawnUTVLVzLBi0Ik6uw_VOodboz2DnuT9p8knB8SdPAxBuwfTDKqpqpSz6oqZbx7_DcP_N8aEnfzs8pX</recordid><startdate>20231227</startdate><enddate>20231227</enddate><creator>Alshammari, Kanan</creator><creator>Alotaibi, Faizah M</creator><creator>Alsugheir, Futoon</creator><creator>Aldawoud, Mohammad</creator><creator>Alolayan, Ashwaq</creator><creator>Algarni, Mohammed Ahmad</creator><creator>Sabatin, Fouad</creator><creator>Mohammad, Mohammad F</creator><creator>Alosaimi, Abdulaziz</creator><creator>Sanai, Faisal M</creator><creator>Odah, Hassan</creator><creator>Alshehri, Ahmed Saleh</creator><creator>Aldibasi, Omar S</creator><creator>Alrehaily, Samah</creator><creator>Al Saleh, Abdullah S</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7795-3609</orcidid><orcidid>https://orcid.org/0000-0002-4120-577X</orcidid><orcidid>https://orcid.org/0000-0002-6712-7888</orcidid><orcidid>https://orcid.org/0000-0002-1626-1059</orcidid></search><sort><creationdate>20231227</creationdate><title>Antibiotic Exposure Concurrently with Anti-PD1 Blockade Therapy Reduces Overall Survival in Patients with Child-Pugh Class A Advanced Hepatocellular Carcinoma</title><author>Alshammari, Kanan ; Alotaibi, Faizah M ; Alsugheir, Futoon ; Aldawoud, Mohammad ; Alolayan, Ashwaq ; Algarni, Mohammed Ahmad ; Sabatin, Fouad ; Mohammad, Mohammad F ; Alosaimi, Abdulaziz ; Sanai, Faisal M ; Odah, Hassan ; Alshehri, Ahmed Saleh ; Aldibasi, Omar S ; Alrehaily, Samah ; Al Saleh, Abdullah S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c489t-bf35d66a6159bacac6fe5e8a043858bca8e340f40f59c1ec212a4405b7275703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibiotics</topic><topic>Bacterial infections</topic><topic>Care and treatment</topic><topic>Cirrhosis</topic><topic>Hepatitis</topic><topic>Hepatocellular carcinoma</topic><topic>Hepatoma</topic><topic>Immune checkpoint inhibitors</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Intestinal microflora</topic><topic>Ipilimumab</topic><topic>Kidney diseases</topic><topic>Kinases</topic><topic>Ligands</topic><topic>Liver cancer</topic><topic>Liver cirrhosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Microbiomes</topic><topic>Microbiota</topic><topic>Microorganisms</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>PD-1 protein</topic><topic>Survival</topic><topic>Urinary tract infections</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alshammari, Kanan</creatorcontrib><creatorcontrib>Alotaibi, Faizah M</creatorcontrib><creatorcontrib>Alsugheir, Futoon</creatorcontrib><creatorcontrib>Aldawoud, Mohammad</creatorcontrib><creatorcontrib>Alolayan, Ashwaq</creatorcontrib><creatorcontrib>Algarni, Mohammed Ahmad</creatorcontrib><creatorcontrib>Sabatin, Fouad</creatorcontrib><creatorcontrib>Mohammad, Mohammad F</creatorcontrib><creatorcontrib>Alosaimi, Abdulaziz</creatorcontrib><creatorcontrib>Sanai, Faisal M</creatorcontrib><creatorcontrib>Odah, Hassan</creatorcontrib><creatorcontrib>Alshehri, Ahmed Saleh</creatorcontrib><creatorcontrib>Aldibasi, Omar S</creatorcontrib><creatorcontrib>Alrehaily, Samah</creatorcontrib><creatorcontrib>Al Saleh, Abdullah S</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alshammari, Kanan</au><au>Alotaibi, Faizah M</au><au>Alsugheir, Futoon</au><au>Aldawoud, Mohammad</au><au>Alolayan, Ashwaq</au><au>Algarni, Mohammed Ahmad</au><au>Sabatin, Fouad</au><au>Mohammad, Mohammad F</au><au>Alosaimi, Abdulaziz</au><au>Sanai, Faisal M</au><au>Odah, Hassan</au><au>Alshehri, Ahmed Saleh</au><au>Aldibasi, Omar S</au><au>Alrehaily, Samah</au><au>Al Saleh, Abdullah S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Antibiotic Exposure Concurrently with Anti-PD1 Blockade Therapy Reduces Overall Survival in Patients with Child-Pugh Class A Advanced Hepatocellular Carcinoma</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2023-12-27</date><risdate>2023</risdate><volume>16</volume><issue>1</issue><spage>133</spage><pages>133-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide with a poor prognosis. Treatment with immune checkpoint inhibitors (ICIs) has improved overall survival in patients with HCC. However, not all patients benefit from the treatment. In this study, 59 patients with HCC were enrolled from two medical centers in Saudi Arabia, with 34% using antibiotics concurrently with their Nivolumab (anti-PD1 blockade). The impact of antibiotic use on the clinical outcomes of patients with HCC undergoing treatment with anti-PD1 blockade was examined. The patients' overall survival (OS) was 5 months (95% CI: 3.2, 6.7) compared to 10 months (95% CI: 0, 22.2) (
= 0.08). Notably, patients with Child-Pugh A cirrhosis receiving anti-PD1 blockade treatment without concurrent antibiotic use showed a significantly longer median OS reaching 22 months (95% CI: 6.5, 37.4) compared to those who were given antibiotics with a median OS of 6 months (95% CI: 2.7, 9.2) (
= 0.02). This difference in overall survival was particularly found in Child-Pugh class A patients receiving anti-PD1 blockade. These findings suggest that antibiotic use may negatively affect survival outcomes in HCC patients undergoing anti-PD1 blockade, potentially due to antibiotic-induced alterations to the gut microbiome impacting the anti-PD1 blockade response. This study suggests the need for careful consideration when prescribing antibiotics to patients with HCC receiving anti-PD1 blockade.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38201560</pmid><doi>10.3390/cancers16010133</doi><orcidid>https://orcid.org/0000-0001-7795-3609</orcidid><orcidid>https://orcid.org/0000-0002-4120-577X</orcidid><orcidid>https://orcid.org/0000-0002-6712-7888</orcidid><orcidid>https://orcid.org/0000-0002-1626-1059</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2023-12, Vol.16 (1), p.133 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10777962 |
| source | MDPI - Multidisciplinary Digital Publishing Institute; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access |
| subjects | Antibiotics Bacterial infections Care and treatment Cirrhosis Hepatitis Hepatocellular carcinoma Hepatoma Immune checkpoint inhibitors Immune system Immunotherapy Intestinal microflora Ipilimumab Kidney diseases Kinases Ligands Liver cancer Liver cirrhosis Medical research Medicine, Experimental Microbiomes Microbiota Microorganisms Patient outcomes Patients PD-1 protein Survival Urinary tract infections |
| title | Antibiotic Exposure Concurrently with Anti-PD1 Blockade Therapy Reduces Overall Survival in Patients with Child-Pugh Class A Advanced Hepatocellular Carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T06%3A26%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Antibiotic%20Exposure%20Concurrently%20with%20Anti-PD1%20Blockade%20Therapy%20Reduces%20Overall%20Survival%20in%20Patients%20with%20Child-Pugh%20Class%20A%20Advanced%20Hepatocellular%20Carcinoma&rft.jtitle=Cancers&rft.au=Alshammari,%20Kanan&rft.date=2023-12-27&rft.volume=16&rft.issue=1&rft.spage=133&rft.pages=133-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16010133&rft_dat=%3Cgale_pubme%3EA779132443%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2912549712&rft_id=info:pmid/38201560&rft_galeid=A779132443&rfr_iscdi=true |